CVR & U.S. FDA: A Meeting of the Minds
Concludes De Novo Pathway Best Suited VANCOUVER, BC / May 9, 2018 / CVR Medical Corp. (TSX.V:CVM) (FRANKFURT: B3BN) (OTCQB: CRRVF) (“CVR Medical”) announces the receipt
Concludes De Novo Pathway Best Suited VANCOUVER, BC / May 9, 2018 / CVR Medical Corp. (TSX.V:CVM) (FRANKFURT: B3BN) (OTCQB: CRRVF) (“CVR Medical”) announces the receipt
CVR Medical Corp. is a med-tech organization dedicated to the development and advancement of revolutionary technology at work within the healthcare sector. Specifically, The Carotid Stenotic Scan (CSS), a groundbreaking tool which will be used to assess Carotid Arterial health in a way which is unavailable to the patient, healthcare provider, and the payor within the current system. By leveraging intellectual property, market and industry know-how, and key strategic relationships, CVR Medical has entered into a trajectory which will revolutionize healthcare and dramatically improve clinical outcomes.